Clinical trial
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck…
NCT00088907 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00088907 |
|---|---|
| Title | Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer |
| Official title | Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer |
| Intervention type | Drug, Other |
| Interventions | docetaxel, placebo, gefitinib |
| Enrollment | 270 |
| Start date | Aug 1, 2004 |
| Primary completion | May 1, 2009 |
| Completion | Aug 1, 2012 |
| First posted | Aug 5, 2004 |
| Last update posted | May 6, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: